HRP20171208T1 - Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 - Google Patents

Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 Download PDF

Info

Publication number
HRP20171208T1
HRP20171208T1 HRP20171208TT HRP20171208T HRP20171208T1 HR P20171208 T1 HRP20171208 T1 HR P20171208T1 HR P20171208T T HRP20171208T T HR P20171208TT HR P20171208 T HRP20171208 T HR P20171208T HR P20171208 T1 HRP20171208 T1 HR P20171208T1
Authority
HR
Croatia
Prior art keywords
group
carbon atoms
acid
hydrogen
alkyl group
Prior art date
Application number
HRP20171208TT
Other languages
English (en)
Croatian (hr)
Inventor
Angelo Guglielmotti
Guido Furlotti
Giorgina Mangano
Nicola Cazzolla
Barbara Garofalo
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of HRP20171208T1 publication Critical patent/HRP20171208T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
HRP20171208TT 2008-03-07 2009-03-05 Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 HRP20171208T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
PCT/EP2009/052585 WO2009109613A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
EP09717638.2A EP2254869B1 (en) 2008-03-07 2009-03-05 Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40

Publications (1)

Publication Number Publication Date
HRP20171208T1 true HRP20171208T1 (hr) 2017-10-06

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171208TT HRP20171208T1 (hr) 2008-03-07 2009-03-05 Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40
HRP20160462TT HRP20160462T1 (hr) 2008-03-07 2009-03-05 Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20160462TT HRP20160462T1 (hr) 2008-03-07 2009-03-05 Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1

Country Status (25)

Country Link
US (3) US8835481B2 (enExample)
EP (3) EP2254869B1 (enExample)
JP (2) JP5509101B2 (enExample)
KR (2) KR101581828B1 (enExample)
CN (2) CN101945855B (enExample)
AR (2) AR070810A1 (enExample)
AU (2) AU2009221083B2 (enExample)
BR (2) BRPI0907976A2 (enExample)
CA (2) CA2712403C (enExample)
CY (2) CY1117584T1 (enExample)
DK (2) DK2254869T3 (enExample)
EA (2) EA019711B1 (enExample)
ES (2) ES2637009T3 (enExample)
GE (2) GEP20135983B (enExample)
HR (2) HRP20171208T1 (enExample)
HU (1) HUE027098T2 (enExample)
IL (3) IL206893A0 (enExample)
LT (1) LT2254869T (enExample)
MX (2) MX2010009626A (enExample)
PL (2) PL2254869T3 (enExample)
PT (1) PT2254869T (enExample)
SG (1) SG188177A1 (enExample)
SI (2) SI2254869T1 (enExample)
UA (2) UA105170C2 (enExample)
WO (2) WO2009109618A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109616A2 (en) * 2008-03-07 2009-09-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
PT2254869T (pt) * 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
CN101959866B (zh) 2008-03-07 2013-10-02 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途
CN102471282A (zh) * 2009-08-03 2012-05-23 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟甲基-1h-吲唑及其衍生物以及所需镁中间体的制备方法
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP3338776A1 (en) * 2012-05-01 2018-06-27 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
ES2612205T3 (es) 2012-05-18 2017-05-12 Sanofi Derivados de pirazol y su uso como antagonistas de LPAR5
US9346757B2 (en) 2012-05-18 2016-05-24 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
AU2013342209B2 (en) 2012-11-09 2016-05-26 Colgate-Palmolive Company Block copolymers for tooth enamel protection
WO2015173786A1 (en) * 2014-05-15 2015-11-19 Boyd Shelley Romayne Compositions and methods for treating and diagnosing ocular disorders
EP3942934A1 (en) * 2015-06-12 2022-01-26 Vettore, LLC Mct4 inhibitors for treating disease
WO2016203313A1 (en) * 2015-06-16 2016-12-22 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
CA3046212A1 (en) 2016-12-12 2018-06-21 Vettore, LLC Heterocyclic inhibitors of mct4
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2024108386A1 (zh) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) * 2023-02-10 2024-08-15 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US364371A (en) * 1887-06-07 peice
US416359A (en) * 1889-12-03 Sash-fastener
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
WO2000078757A1 (en) 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
ATE417617T1 (de) 2001-03-15 2009-01-15 Seikagaku Kogyo Co Ltd Mittel zur steurung der expression von il-12
CA2468349A1 (en) 2001-11-30 2003-06-12 Synta Pharmaceuticals Corporation Pyrimidine compounds
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
WO2006046739A1 (ja) * 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
WO2006060194A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
WO2009109616A2 (en) 2008-03-07 2009-09-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
CN101959866B (zh) 2008-03-07 2013-10-02 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途
PT2254869T (pt) 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40

Also Published As

Publication number Publication date
IL207131A0 (en) 2010-12-30
MX2010009626A (es) 2010-12-20
JP5509099B2 (ja) 2014-06-04
GEP20135912B (en) 2013-08-26
CN101952256A (zh) 2011-01-19
JP5509101B2 (ja) 2014-06-04
PT2254869T (pt) 2017-07-18
AU2009221089A1 (en) 2009-09-11
JP2011513367A (ja) 2011-04-28
DK2254870T3 (en) 2016-05-17
JP2011513365A (ja) 2011-04-28
ES2569330T3 (es) 2016-05-10
EP2254870A2 (en) 2010-12-01
CA2712403C (en) 2017-06-06
SG188177A1 (en) 2013-03-28
PL2254870T3 (pl) 2016-07-29
SI2254869T1 (sl) 2017-10-30
EA018241B1 (ru) 2013-06-28
CN101945855B (zh) 2014-12-17
EA201071038A1 (ru) 2011-02-28
US20110003874A1 (en) 2011-01-06
PL2254869T3 (pl) 2017-10-31
BRPI0907976A2 (pt) 2015-08-04
LT2254869T (lt) 2017-08-10
IL215579A (en) 2015-06-30
MX2010009623A (es) 2010-09-28
ES2637009T3 (es) 2017-10-10
AR070810A1 (es) 2010-05-05
AR070811A1 (es) 2010-05-05
DK2254869T3 (en) 2017-09-04
CA2712403A1 (en) 2009-09-11
US7919518B2 (en) 2011-04-05
GEP20135983B (en) 2013-12-10
WO2009109613A3 (en) 2009-12-10
UA103605C2 (en) 2013-11-11
WO2009109613A2 (en) 2009-09-11
US8283348B2 (en) 2012-10-09
HUE027098T2 (en) 2016-08-29
CN101945855A (zh) 2011-01-12
CN101952256B (zh) 2016-03-16
CY1117584T1 (el) 2017-04-26
EP3181551A1 (en) 2017-06-21
BRPI0907977A2 (pt) 2015-08-04
EP2254869A2 (en) 2010-12-01
IL206893A0 (en) 2010-12-30
SI2254870T1 (sl) 2016-05-31
UA105170C2 (en) 2014-04-25
US20110160205A1 (en) 2011-06-30
WO2009109618A2 (en) 2009-09-11
CA2712703C (en) 2016-10-11
EA201071040A1 (ru) 2011-02-28
CY1119252T1 (el) 2018-02-14
IL215579A0 (en) 2011-11-30
WO2009109618A3 (en) 2009-12-10
US8835481B2 (en) 2014-09-16
IL207131A (en) 2013-02-28
CA2712703A1 (en) 2009-09-11
AU2009221083B2 (en) 2013-11-28
KR101581828B1 (ko) 2015-12-31
AU2009221089B2 (en) 2013-12-05
HRP20160462T1 (hr) 2016-06-03
EP2254869B1 (en) 2017-05-31
KR20100131432A (ko) 2010-12-15
KR101599867B1 (ko) 2016-03-04
EA019711B1 (ru) 2014-05-30
AU2009221083A1 (en) 2009-09-11
EP2254870B1 (en) 2016-02-24
KR20100133957A (ko) 2010-12-22
US20100311744A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
HRP20171208T1 (hr) Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40
HRP20191953T1 (hr) DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CXCR1 i p40
ES2984482T3 (es) Pirazolo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
JP2024514703A (ja) ピペラジン構造を有するｐａｒｐ阻害剤、その調製方法およびその医薬的使用
PE20220143A1 (es) Agonistas de glp-1r y usos de los mismos
HRP20241656T1 (hr) Derivat nitrila koji djeluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
HRP20160457T1 (hr) Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
HRP20090577T8 (en) Use of crth2 antagonist compounds in therapy
HRP20130900T1 (hr) Derivat (aza)indola i njegova uporaba u medicinske svrhe
HRP20151078T1 (hr) Pirazoli kao 11-beta-hsd-1
PE20141788A1 (es) Derivados de betulina
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
CA2758474A1 (en) Novel p2x7r antagonists and their use
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
CO7200248A2 (es) Derivados de etinilo como moduladores de la actividad de los receptores mglur5
MA32108B1 (fr) Derives d'indazole
ECSP077160A (es) Nuevos d-homo-estra-1,3,5(10)-trienos sustituidos en la posición 2 como inhibidores de 17 -hidroxiesteroide deshidrogenasa tipo 1
WO2019241213A1 (en) 2-naphthimidamides, analogues thereof, and methods of treatment using same
JP2009040767A5 (enExample)
HRP20140326T1 (hr) Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat